Our previous study confirmed that Cyr61 levels are elevated in the bone marrow of patients with ALL, and increased Cyr61 promotes ALL cell survival and decreases the chemosensitivity of ALL cells to cytarabine (Cao et al. 2019). The gene discussed is CCN1; the disease is acute lymphoblastic leukemia.